0
Checkpoint Therapeutics, Inc. Banner Image

Checkpoint Therapeutics, Inc. has reached its limit for free report views

Work for Checkpoint Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Checkpoint Therapeutics, Inc.

  • Ticker CKPT
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Checkpoint Therapeutics, Inc. Logo Image
  • 1-10 Employees
  • Based in New York City, New York
Checkpoint Therapeutics, Inc. (“Checkpoint”) is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-PD-L1 antibody licensed from the Dana-Farber Cancer InstituteMore, in an ongoing global, open-label, multicohort Phase 1 clinical trial in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers, including ongoing cohorts in locally advanced and metastatic cutaneous squamous cell carcinoma intended to support one or more applications for marketing approval. In addition, Checkpoint is evaluating its lead small-molecule, targeted anti-cancer agent, CK-101, a third-generation epidermal growth factor receptor (“EGFR”) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Checkpoint is headquartered in New York City and was founded by Fortress Biotech, Inc.
Checkpoint Therapeutics, Inc.

Most Recent Annual Report

Checkpoint Therapeutics, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Checkpoint Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports